Ultragenyx Pharmaceutical Inc. RARE R3KPHARMA
Company Overview
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Why Investors Should Care
Revenue has grown at a 190.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $673.00M (+20.2% YoY); net profit $-575.00M.
- Trailing 12 Months Year-on-year growth — revenue +28.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 190.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 190.42% |
| 1 Year: | 28.10% |
Stock Price Performance
| 1 Year: | -48.64% |
| 6 Months: | -34.19% |
| 3 Months: | -31.08% |
| 1 Month: | -42.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)20.62 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 190.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 59.3% below its 52-week high.
- RSI at 21 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RARE Ultragenyx Pharmaceutical Inc. R3KPHARMA | 14.88 | -2.55 | $1.47B | 0.00% | -46.60% | - | 190.42% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 198.00K | 2.41M | 10.68M | 12.79M | 11.76M | 16.26M | 18.17M | 24.15M | 25.80M | 35.59M | 36.31M | 61.71M | 81.47M | 91.54M | 99.39M | 86.97M | 81.65M | 79.94M | 89.34M | 90.70M | 100.50M | 108.31M | 98.05M | 108.83M | 147.03M | 139.49M | - | 139.00M | 166.50M | 159.93M | 207.28M | 136.00M | 214.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.00M | 23.00M | 27.99M | 29.34M | 30.00M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 110.00M | 143.49M | 131.94M | 177.93M | 106.00M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 253.00M | 251.38M | 302.83M | 291.22M | 275.00M | - |
| Operating Income | - | -53.62M | -58.05M | -65.78M | - | -69.95M | -78.44M | -83.71M | - | -96.49M | -94.90M | -89.65M | - | -99.21M | -112.47M | -118.03M | - | -120.67M | -63.05M | -50.31M | - | -106.57M | -82.78M | -89.83M | -136.63M | -141.59M | -225.07M | -154.10M | -147.96M | -145.10M | -165.35M | -116.36M | -131.99M | - | -143.00M | -107.89M | -170.89M | -113.28M | -169.00M | -75.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -127.00M | -91.35M | -156.79M | -99.43M | -155.00M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.00M | 14.04M | 14.15M | 19.47M | 21.00M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -150.00M | -114.00M | -179.54M | -127.69M | -184.00M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00M | 947.00K | 873.00K | 870.00K | 1.00M | - |
| Net Income | -55.22M | -52.76M | -56.92M | -64.91M | -71.29M | -68.29M | -72.89M | -79.23M | -81.73M | 30.25M | -52.73M | -87.31M | -87.83M | -96.76M | -99.17M | -112.99M | -93.81M | -119.03M | 25.32M | -68.84M | -24.01M | -136.14M | -122.43M | -73.00M | -152.32M | -158.16M | -245.11M | -163.97M | -159.83M | -159.65M | -170.68M | -131.60M | -133.52M | - | -151.00M | -114.95M | -180.41M | -128.56M | -185.00M | -92.00M |
| Diluted EPS | - | - | - | - | - | -1.63 | - | - | - | 0.62 | -1.06 | -1.74 | -1.73 | -1.82 | -1.72 | - | - | -2.05 | 0.41 | -1.13 | -0.37 | - | -1.81 | -1.08 | -2.19 | -2.26 | -3.50 | -2.33 | -2.25 | -2.23 | -2.03 | -1.52 | -1.40 | - | -1.57 | -1.17 | -1.81 | -1.29 | -1.84 | -0.90 |
| R&D Expense | - | 40.41M | 43.33M | 48.71M | - | 51.27M | 58.44M | 60.41M | - | 75.50M | 76.83M | 70.04M | - | 78.11M | 96.05M | 100.14M | - | 112.96M | 80.71M | 87.31M | - | 147.52M | 113.20M | 113.42M | 143.16M | 154.53M | 237.30M | 165.70M | 164.95M | 157.25M | 178.49M | 161.50M | 170.11M | - | 166.00M | 164.74M | 216.21M | - | 187.00M | 167.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 133.00K | 2.61M | 51.49M | 103.71M | 271.03M | - | 363.33M | 434.00M | 560.00M | 673.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 28.32M | 45.00M | 77.00M | 109.00M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 335.01M | 389.00M | 483.00M | 564.00M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 983.93M | 958.00M | 1.02B | 1.10B |
| Operating Income | -15.98M | -32.28M | -56.78M | -147.74M | -248.01M | -328.94M | -371.37M | -424.17M | -330.12M | - | -648.92M | -569.00M | -536.00M | -535.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -640.49M | -517.00M | -468.00M | -474.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 43.02M | 66.00M | 63.00M | 62.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -701.73M | -609.00M | -567.00M | -571.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 5.70M | -2.00M | 2.00M | 4.00M |
| Net Income | -16.33M | -35.07M | -59.80M | -145.62M | -245.87M | -302.14M | -197.61M | -402.73M | -186.57M | - | -707.42M | -607.00M | -569.00M | -575.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | -3.07 | - | -10.12 | -8.25 | -6.29 | -5.83 |
| R&D Expense | 12.64M | 27.83M | 45.97M | 114.74M | 183.20M | 231.64M | 294.00M | 357.36M | 412.08M | 497.15M | 705.79M | 648.00M | 698.00M | 750.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 59.65M | 197.97M | 559.57M | 540.63M | 490.75M | 719.56M | 1.14B | 1.76B | - | 1.55B | 1.49B | 1.50B | 1.53B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 883.90M | 732.18M | 817.00M | 951.00M |
| Cash & Equivalents | 10.64M | 86.19M | 7.43M | 24.32M | 93.57M | 161.12M | 100.49M | 113.43M | 433.58M | 713.53M | - | 132.94M | 213.58M | 174.00M | 421.00M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 26.77M | 33.97M | 45.00M | 52.00M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 40.45M | 73.39M | 122.00M | 158.00M |
| Total Liabilities | - | - | 9.54M | 13.02M | 28.48M | 66.65M | 107.30M | 110.65M | 481.73M | 605.18M | - | 1.19B | 1.22B | 1.24B | 1.60B |
| Current Liabilities | - | - | 5.92M | 12.52M | 27.92M | 60.26M | 71.01M | 74.72M | 103.30M | 189.61M | - | 261.21M | 280.44M | 344.00M | 384.00M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 31.59M | 43.17M | 40.00M | 36.00M |
| Total Equity | -7.96M | -27.05M | -74.82M | 184.94M | 531.09M | 473.97M | 383.45M | 608.91M | 653.76M | 1.15B | - | 352.49M | 275.41M | 255.00M | -80.00M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 70.20M | 82.33M | 92.55M | 96.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -160.97M | -253.84M | -290.57M | -345.38M | -132.22M | - | -380.46M | -475.00M | -414.00M | -466.00M |
| Investing Cash Flow | - | - | - | - | 91.12M | 55.48M | -33.33M | -13.04M | -179.12M | - | -291.65M | 168.00M | -18.00M | 236.00M |
| Financing Cash Flow | - | - | - | - | 138.68M | 136.27M | 336.85M | 679.31M | 600.27M | - | 501.21M | 388.00M | 399.00M | 478.00M |
| Capital Expenditure | -1.09M | -407.00K | -2.15M | -4.96M | -10.19M | -2.79M | -4.08M | -24.83M | -43.91M | - | -146.12M | -47.00M | -20.00M | -21.00M |
| Free Cash Flow | - | - | - | - | -171.16M | -256.64M | -294.64M | -370.21M | -176.12M | - | -526.59M | -522.00M | -434.00M | -487.00M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -170.91M | 81.00M | -33.00M | 248.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | 92.2% | 89.6% | 86.2% | 83.8% |
| Operating Margin % | - | - | - | - | -186,471.4% | -12,593.5% | -721.2% | -409.0% | -121.8% | - | -178.6% | -131.1% | -95.7% | -79.5% |
| Net Margin % | - | - | - | - | -184,867.7% | -11,567.3% | -383.7% | -388.3% | -68.8% | - | -194.7% | -139.9% | -101.6% | -85.4% |
| ROE % | 60.4% | 46.9% | -32.3% | -27.4% | -51.9% | -78.8% | -32.5% | -61.6% | -16.2% | - | -200.7% | -220.4% | -223.1% | 718.8% |
| ROCE % | - | -60.1% | -30.6% | -27.8% | -51.6% | -78.4% | -57.6% | -41.1% | -21.0% | - | -50.5% | -47.0% | -46.2% | -46.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.81% | 10.65M | $154.59M |
| 2 | RTW Investments LP | 7.91% | 7.80M | $113.13M |
| 3 | Vanguard Portfolio Management LLC | 6.89% | 6.79M | $98.52M |
| 4 | AQR Capital Management, LLC | 6.65% | 6.56M | $95.20M |
| 5 | State Street Corporation | 6.25% | 6.16M | $89.36M |
| 6 | Vanguard Capital Management LLC | 4.36% | 4.30M | $62.34M |
| 7 | Two Sigma Investments, LP | 3.67% | 3.62M | $52.54M |
| 8 | Sands Capital Management, LLC | 3.20% | 3.16M | $45.83M |
| 9 | Jacobs Levy Equity Management, Inc. | 2.98% | 2.94M | $42.66M |
| 10 | Frontier Capital Management Company LLC | 2.89% | 2.85M | $41.32M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RARE
Pharvaris’ stock jumps on pivotal success in rare genetic disease - Endpoints News
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQdlVncEl4Xy1RZm0yNHd5Ym5OeGpVUE5SNktZNVdqRHphNTVZRGo5RmtodjVoMjAtZ091UmdMU2pZcjdQWnhURERPb3kxYzRwZVItdHZaNEVKdUUyUXM2dXN0eDhhbXFPMGJoeDIxVURxQjNFcE8zS0FIanBtNFljX2c4ejRmRE9CY3BnSX…
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQV3o5TXdDTmUtM3N6VU56bnY3SkE4dTRkTmlJcU1PLWVIWnB6Ym5tZ3pDVjZXN2hNcjh0SWt5SVZJUmxOektXdkxKX2dxRzRfNHUzTk0yME5qS0pUbklEVmVpbG1yMEdidGxHOXFNY3BwdVVKT3dBZXJUdXdHOUVaTVMxWTRmR2lqZV9GQj…
Ultragenyx (NASDAQ: RARE) exec sells 161 shares for RSU tax, keeps 69,146 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNEFLVFRlM19RdkxCMkltMWRjcUx4bFM3U1d2RFlKZEFWRzB4NHl6Y1VmVFY4NEhKZGVZMHpVaERwdHRfdThRcEZRZmRrcnBsRzNBd1MzWFI5THFNeXRUdExNZExzVW1pV0IxMjk3SjNpWEV1SnNTSzZITzVuY0kyUTF3bEg4MHVubUkzdl…
Why USA Rare Earth Stock Surged 19.2% Last Month - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNRUg0ME9uS3k0ekZkQ1Y0Y1IwU0lpN0REQlNmZXJBVF9GRHMyZWdwUkVoZjF5bnhVd3IxUUlrY3dEVDd2RXFpcS1aRm14WndzLXRfRTF6WmZ0SEU0TWItQVdLaHF2N3hpY1FuX3IycnliVGpWVHJ0U2VaMmlHU3d2TURmVllZRVhGa1FHel…
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOUU9scE1oaExDa3RxTHVYU2NyU1E1R09wNlI2Z3ItTENRM0lZNVFxcmpNbWE1Q1N6T3pjYTl6dHp6UXA0YWNCUW5rZi1OUzNBZEYtbUVJYV82VlNGNHFKTFMzSkQzYUMzWV9oTnlzUS16TEdCc3F1eEZaYzlCZEVDUkFqOVhyMXRuMHZjRj…
Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOSFlIY1hKMlExSDlIZFdGTFVPRkI4Q1ltd256YXF1My1nSkptOEJmbkpSd3FEOXJhYWJoUURrYjl0UlQyaFlHT3ZfR1hLbnlleTgyNmZzVWJpRGRYTm1RbHFXSGMtQnlvc0RHdGxUTzVQU0RvdEpCT1VMZnFuN0JqejY4bEFkVG1xZThoaG…
RARE — Frequently Asked Questions
What is the current share price of Ultragenyx Pharmaceutical Inc. (RARE)?
As of 2026-09-19 21:16 PDT, Ultragenyx Pharmaceutical Inc. (RARE) trades at $14.88 on NasdaqGS. Its 52-week range is $14.85 to $36.54.
What is the market capitalisation of RARE?
Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalisation of $1.47B on NasdaqGS.
What is the P/E ratio of RARE?
RARE trades at a trailing price-to-earnings (P/E) ratio of -2.55. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -4.90.
Is RARE a good stock to buy?
This page provides a data-driven analysis of Ultragenyx Pharmaceutical Inc. (RARE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.